BioCentury | Mar 21, 2016
Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
BC Week In Review | Jan 19, 2015
Company News

PharmAbcine, 3SBio deal

PharmAbcine granted 3SBio an exclusive license to develop, manufacture and market DIG-KT in Taiwan, Korea and China, including Macau and Hong Kong. PharmAbcine will receive an undisclosed upfront payment and is eligible for milestones and...
BC Extra | Jan 16, 2015
Company News

China's 3SBio in-licenses second PharmAbcine mAb

PharmAbcine Inc. (Daejon, South Korea) granted 3SBio Inc. (Shenyang, China) an exclusive license to develop DIG-KT ( TRPH 011 ) in greater China and Korea. The bispecific antibody against vascular endothelial growth factor (VEGF) receptor 2 ( KDR/Flk-1...
BC Extra | Jan 16, 2015
Company News

China's 3SBio in-licenses second PharmAbcine mAb

PharmAbcine Inc. (Daejon, South Korea) granted 3SBio Inc. (Shenyang, China) an exclusive license to develop DIG-KT ( TRPH 011 ) in greater China and Korea. The bispecific antibody against vascular endothelial growth factor (VEGF) receptor 2 ( KDR/Flk-1...
Items per page:
1 - 4 of 4